TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9133220
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine test
Study: 9133220
Drug: Oral guanfacine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral guanfacine test
Study: 26700096
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of fish oil (0.6 g/day of EPA and DHA) for 9 weeks
Study: 20582542
Drug: Preincisional parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Preincisional parecoxib (40 mg IV 30 min before skin incision)
Study: 20582542
Drug: Postincisional parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Postincisional parecoxib (40 mg IV 30 min after skin incision)
Study: 20582542
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received patient-controlled analgesia (PCA) morphine
Study: 15679759
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg b.d.
Study: 12358621
Drug: Artemisinin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin (40 mg/kg over 3 days) plus placebo chloroquine
Study: 12358621
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over 3 days) plus placebo artemisinin
Study: 10366800
Drug: SCF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCF plus G-CSF
Study: 17163251
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine
Study: 23074206
Drug: PF‐04523655 3‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04523655 3‐mg intravitreal injections
Study: 23074206
Drug: PF‐04523655 0.4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04523655 0.4‐mg intravitreal injections
Study: 23074206
Drug: PF‐04523655 1‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐04523655 1‐mg intravitreal injections
Study: 20925948
Drug: Tailored home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored home-based exercise twice weekly
Study: 20925948
Drug: Group-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based exercise twice weekly in rehabilitation center
Study: 18410585
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg melatonin and 100 mg SB‐73
Study: 18410585
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Acyclovir
Study: 1957409
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg, supplemented with half of the initial dosage if necessary)
Study: 1957409
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg, supplemented with half of the initial dosage if necessary)
Study: 7343284
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU heparin-dihydroergotamine mesylate (Dihydergot)
Study: 27819489
Drug: Progesterone (1
Normalized name: Fluorofuranylnorprogesterone (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (1 mg kg‐1 per 12 hours for 5 days)
Study: 26449164
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for 48 weeks followed by treatment interruption (TI)
Study: 23726041
Drug: Lebrikizumab 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 500 mg
Study: 23726041
Drug: Lebrikizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab (all doses)
Study: 17610805
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies targeting postprandial hyperglycemia
Study: 15096971
Drug: N-13 ammonia
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-13 ammonia (600 MBq or 16 mCi) administered intravenously
Study: 11243303
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 4 mg to 8 mg once daily
Study: 11243303
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 10 mg to 20 mg once daily
Study: 9562226
Drug: Inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid plus theophylline
Study: 9562226
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the steroid dose
Study: 28576451
Drug: Elbasvir 50
Normalized name: elbasvir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (immediate treatment group)
Study: 28576451
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for 12 weeks (deferred treatment group)
Study: 25519790
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment group
Study: 26070127
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen (estriol 50 μg/g gel, twice a week for 12 weeks)
Study: 26070127
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid vaginal gel (once a day for 12 weeks)
Study: 21548209
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil every other day for 12 weeks
Study: 21548209
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E at 100 mg once a day for 12 weeks (Control)
Study: 8067497
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day for 1 week, then 40 mg/day for 5 weeks)
Study: 27684533
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of trastuzumab and lapatinib
Study: 19420195
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg three times daily for 28 days
Study: 11728297
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide therapy
Study: 15253732
Drug: Ramipril (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (6 mg/m2)
Study: 11236072
Drug: Citalopram 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 60 mg/day
Study: 11236072
Drug: Citalopram (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (all doses)
Study: 11236072
Drug: Citalopram 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 60 mg and 20 mg
Study: 9305229
Drug: Live active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live active yogurt containing L. acidophilus (225 g twice daily)
Study: 9305229
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (yogurt without L. acidophilus)
Study: 9305229
Drug: Live active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live active yogurt containing L. acidophilus
Study: 3084344
Drug: Bowel rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bowel rest with parenteral nutrition
Study: 9058440
Drug: Oral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diet
Study: 22795063
Drug: Moderate potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate potassium cold blood cardioplegia (K+, 10 mmol/L)
Study: 22795063
Drug: High potassium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High potassium cold blood cardioplegia (K+, 20 mmol/L)
Study: 19477776
Drug: Androgen ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablation treatment
Study: 19477776
Drug: Literature on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literature on female breast cancer patients treated with hormones
Study: 1852979
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks oral digoxin administration
Study: 6334320
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base as enteric coated pellets (2 X 250 mg)
Study: 6334320
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate tablet (1 X 500 mg)
Study: 6334320
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate sachet (1 X 500 mg)
Study: 31745048
Drug: Mini-implant anchorage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implant anchorage system
Study: 30470323
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (Pain Course)
Study: 27631178
Drug: Calcitriol supplementation
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol supplementation (25 µg) plus hypocaloric diet
Study: 21950736
Drug: Caffeine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2 × 200 mg)
Study: 21950736
Drug: Modafinil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (2 × 100 mg)
Study: 17614214
Drug: Intervention materials
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention materials for smokers in contemplation, preparation, action, and maintenance
Study: 9792578
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment (continuous positive airway pressure)
Study: 65221
Drug: MOPP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP and ABDV chemotherapy with local radiotherapy
Study: 30352537
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral morphine administration
Study: 23333117
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (carboplatin and paclitaxel)
Study: 23333117
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with standard chemotherapy
Study: 17512159
Drug: Assessment period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment period before treatment entry
Study: 17512159
Drug: Treatment entry
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment entry period
Study: 11713727
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment on the control side
Study: 8004613
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for younger or premenopausal women
Study: 8004613
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen for older or postmenopausal women with estrogen receptor-positive tumors
Study: 8004613
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (general)
Study: 3555968
Drug: bufexamac (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: bufexamac (20 mg)
Study: 3555968
Drug: methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone (40 mg)
Study: 21110088
Drug: Low MeHg
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low MeHg (0.76 mg kg⁻¹)
Study: 21110088
Drug: Medium MeHg
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium MeHg (7.88 mg kg⁻¹)
Study: 21110088
Drug: High MeHg
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High MeHg (16.22 mg kg⁻¹)
Study: 21110088
Drug: Control (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.04 mg kg⁻¹)
Study: 12660669
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 mL of 1.4%-4.6% NaCl) twice a day for 6 to 12 days.
Study: 12660669
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500-1000 mg) as bolus twice a day for 6 to 12 days without HSS.
Study: 9365428
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL syrup of ipecac administered at 5 minutes after ingestion of 3900 mg acetaminophen
Study: 9365428
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL syrup of ipecac administered at 30 minutes after ingestion of 3900 mg acetaminophen
Study: 9365428
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL syrup of ipecac administered at 60 minutes after ingestion of 3900 mg acetaminophen
Study: 9365428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ipecac administration)
Study: 8261835
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg twice a day
Study: 8261835
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg twice a day
Study: 3493854
Drug: Trivalent live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live, oral polio vaccine (Sabin)
Study: 3493854
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received initial dose at 2 months of age)
Study: 31216297
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment
Study: 29609704
Drug: Non-CPAP (best
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CPAP (best medical treatment)
Study: 25344393
Drug: TEAMS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAMS therapy plus treatment‐as‐usual (TAU)
Study: 18283036
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m(2) (P500)
Study: 18283036
Drug: Pemetrexed 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 900 mg/m(2) (P900)
Study: 11824857
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (increased to 10 mg if needed)
Study: 11824857
Drug: Chlorthalidone 15
Normalized name: chlorthalidone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 15 mg (increased to 30 mg if needed)
Study: 31827356
Drug: Inhaled 1600
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 1600 μg Salbutamol (SAL)
Study: 23866771
Drug: Usual DVA
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual DVA agency support plus psychological intervention (SPA sessions weekly or fortnightly, with two follow-up sessions at 1 month and 3 months)
Study: 19946937
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (aripiprazole and risperidone)
Study: 17562526
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Diazepam (DZP) in older subjects
Study: 17562526
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Diazepam (DZP) in young subjects
Study: 17562526
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Diazepam (DZP) in young subjects
Study: 11848262
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg perindopril
Study: 2175584
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril
Study: 2864420
Drug: Oral phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phenytoin formulations (5 different formulations, 300 mg each)
Study: 2864420
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin (300 mg)
Study: 27029681
Drug: Deferiprone alone
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone alone (75 mg/kg/day in 3 divided doses)
Study: 27029681
Drug: Deferasirox alone
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox alone (30 mg/kg/day single dose)
Study: 27029681
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (same doses as monotherapy)
Study: 27029681
Drug: Deferiprone and
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone and Deferasirox (monotherapy and combination)
Study: 23257371
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (>200 mg daily)
Study: 23257371
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (≤200 mg daily)
Study: 20132540
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation intervention (brief motivational interview, intensive motivational interview with pharmacotherapy, reinforcing intervention)
Study: 15966884
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix proteins (EMPs, Emdogain Gel)
Study: 15966884
Drug: Tetracycline-coated e-PTFE
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline-coated e-PTFE membrane (MEMP) adjunct to EMP
Study: 12839637
Drug: Millimeter wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimeter wave irradiation and routine medication
Study: 12839637
Drug: Pretending millimeter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretending millimeter wave irradiation and routine medication
Study: 10341371
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of prednisone (n = 12)
Study: 8607399
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (A: 50,000 IU/day, C: 1,000 mg/day, E: 400 mg/day, beta-carotene: 25 mg/day)
Study: 2013589
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression and aspirin
Study: 2013589
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression and low-dose warfarin
Study: 27287084
Drug: LNG/EE extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE extended regimen (84 days of LNG 150 µg/EE 30 µg with 7 days of EE 10 µg)
Study: 27287084
Drug: LNG/EE 21/7
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE 21/7 (21 days of LNG 100 µg/EE 20 µg with 7 days of placebo)
Study: 24901757
Drug: Robotic knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic knee brace therapy
Study: 18818160
Drug: Purple sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple sweet potato leaves (PSPL) 200 g/d containing 902 mg polyphenols
Study: 16328673
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (L-B) for local infiltration and intraperitoneal instillation
Study: 16328673
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) for local infiltration and Levobupivacaine 0.25% (L-B) for intraperitoneal instillation
Study: 16328673
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (L-B) for intraperitoneal instillation and Normal saline (NS) for local infiltration
Study: 16328673
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (L-B) for both local infiltration and intraperitoneal instillation
Study: 14585107
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (traditional dietary treatment)
Study: 8744662
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15 mL saline (M)
Study: 8744662
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15 mL 0.5% bupivacaine (MIB)
Study: 8744662
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 15 mL 0.5% bupivacaine at the L3‐L4 level (MEB)
Study: 31671757
Drug: Iron (5
Normalized name: iron/folic acid/C/B12/biotin 75 mg iron (5 mg-70 mg)-1 mg-175 mg-120 mcg-300 mcg ORAL CAPSULE, EXTENDED RELEASE MULTIPHASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (5 mg) and Galacto-Oligosaccharides (7.5 g)
Study: 31671757
Drug: Iron (5
Normalized name: iron/folic acid/C/B12/biotin 75 mg iron (5 mg-70 mg)-1 mg-175 mg-120 mcg-300 mcg ORAL CAPSULE, EXTENDED RELEASE MULTIPHASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (5 mg)
Study: 26017328
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg/day
Study: 24558835
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (as basic treatment)